- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05319509
Pilot Study of Virtual Reality Therapy for Students With Anxiety
June 9, 2025 updated by: Jack Tsai, The University of Texas Health Science Center, Houston
The purpose of this study is to assess changes in self-reported anxiety over the course of six virtual reality (VR) sessions and to assess changes in academic self-efficacy, as well as examine the feasibility and acceptability of a relatively short and time intensive VR intervention (i.e.,six sessions over the course of three weeks) for reducing anxiety symptoms in college students.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tsai Jack, PhD
- Phone Number: 210-276-9022
- Email: Jack.Tsai@uth.tmc.edu
Study Contact Backup
- Name: Abigail Lipe
- Phone Number: 210-722-8218
- Email: Abigail.R.Lipe@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- Tsai Jack, PhD
- Phone Number: 210-276-9022
- Email: Jack.Tsai@uth.tmc.edu
-
Contact:
- Abigail Lipe
- Phone Number: 210-722-8218
- Email: Abigail.R.Lipe@uth.tmc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- enrolled in The University of Texas Health Science Center School of Public Health San Antonio regional campus
- competent in English
- total score of at least 3 on the Generalized Anxiety Disorder (GAD-2)
Exclusion Criteria:
- Currently receiving psychological treatment for anxiety symptoms, or has received treatment in the last year.
- Report photosensitive epilepsy.
- Report stereoscopic vision or balance problems
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: gameChange
|
Staff will explain the rationale behind gameChange, and briefly explain the different scenarios: a doctor's office, a waiting room, a pub, a café, a grocery store, a public street and a bus.
Each scenario contains five levels, each increasing with anxiety stimuli and certain tasks the participant must complete.
The participant will put on the Oculus headset, and go through a preliminary orientation game.
The headset will be casted to an external monitor.
Once they start gameChange, it will take the participants to the virtual therapist's room.
They will be asked to choose which scenario they would like to participate in first and will complete all five levels for one scenario.
Research staff will be taking event sampling-style observations of the participant.
After completion of the levels, the participant will return to the virtual therapist's room for debriefing, and then will be asked to exit the game.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in state anxiety as assessed by the Liebowitz Social Anxiety Scale-Self Report version (LSAS-SR)
Time Frame: before first session in week 1, before third session in week 2 and before sixth session in week 3
|
The LSAS-SR questionnaire is composed of 24 items divided into 2 subscales, 13 concerning performance anxiety, and 11 pertaining to social situations.
The 24 items are first rated on a Likert Scale from 0(none) to 3(severe) on fear felt during the situations, and then the same items are rated from 0(never)-3(usually)regarding avoidance of the situation.
Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points.
Score of 30 or less indicates social anxiety disorder(SAD) is unlikely, score of 30-60 shows that SAD is probable and score 60-90 indicates that SAD is highly probable.
|
before first session in week 1, before third session in week 2 and before sixth session in week 3
|
|
Change in depressive symptoms as assessed by score on the Patient Health Questionnaire-4 (PHQ-4)
Time Frame: Baseline(before the first session in week 1)
|
The PHQ-4 questionnaire consists of 4 questions and each is rated on a 4 point scale from 0(not at all) to 3(every day) for a maximum score of 12,a higher number indicating a worse outcome.
|
Baseline(before the first session in week 1)
|
|
Change in anxiety related behaviors such as rate of speech
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in anxiety related behaviors such as volume of speech
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in anxiety related behaviors such as Negative self-talk
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in anxiety related behaviors such as Utterances about experience
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in anxiety related behaviors such as Laughter
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in Psychomotor agitation such as pacing
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in Psychomotor agitation such as Fidgeting
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in Psychomotor agitation such as Rubbing hands/neck/head
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
|
Change in physiology such as perspiration
Time Frame: Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Anxiety-related behaviors will be recorded using an event sampling observation guide
|
Week 1(session1 and session 2), week 2( session 3 and session 4), week 3 (session 5 and session 6)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in self-reported academic performance as assessed by the Motivated Strategies for Learning Questionnaire (MSLQ)
Time Frame: before first session in week 1, before third session in week 2 and before sixth session in week 3
|
The MSLQ questionnaire consists of 9 questions each one is scored from 1= not at all true of me to 7=very true of me, a higher number indicating a better outcome with a maximum score of 63
|
before first session in week 1, before third session in week 2 and before sixth session in week 3
|
|
change in feasibility as assessed by the rating on a short questionnaire
Time Frame: after the third session in week 2 , after sixth session in week 3
|
The usability questionnaire is developed by gameChange about the ease of VR software use, believability of VR environment, and level of engagement.
this consists of 5 questions and each one is scored form 1(very difficult) to 5(very easy) for a maximum score of 25, a higher number indicating more easiness in using the VR software
|
after the third session in week 2 , after sixth session in week 3
|
|
Change in acceptability as assessed by the rating on a short questionnaire
Time Frame: after the third session in week 2 , after sixth session in week 3
|
The usability questionnaire is developed by gameChange about the ease of VR software use, believability of VR environment, and level of engagement.
this consists of 5 questions and each is scored form 1(strongly disagree) to 5(strongly agree) for a maximum score of 25
|
after the third session in week 2 , after sixth session in week 3
|
|
Change in perceived presence in the virtual environment (as indicated by continuous score on the Igroup Presence Questionnaire (IPQ)
Time Frame: after the third session in week 2 and the sixth session in week 3
|
There are 14 questions and each one is scored form -3 to +3.
A total negative score indicates that the participant personally felt very disconnected from VR world, and that they lacked believable presence within world, and rather felt like they were manipulating a machine from an outside perspective.
|
after the third session in week 2 and the sixth session in week 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Tsai Jack, PhD, The University of Texas Health Science Center, Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2022
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
August 1, 2027
Study Registration Dates
First Submitted
March 31, 2022
First Submitted That Met QC Criteria
March 31, 2022
First Posted (Actual)
April 8, 2022
Study Record Updates
Last Update Posted (Actual)
June 12, 2025
Last Update Submitted That Met QC Criteria
June 9, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-SPH-21-0935
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
University of CalabriaNot yet recruitingAnxiety | Anxiety Disease | Anxiety and Distress | Public Speaking AnxietyItaly
-
Clinica Alemana de SantiagoUniversidad del DesarrolloRecruitingAnxiety | Induction of Anesthesia | Anxiety Preoperative | Technology Use | Child Anxiety | Anesthesia Care | Anxiety After SurgeryChile
-
Boston Medical CenterPatient-Centered Outcomes Research Institute; Boston University; Johns Hopkins... and other collaboratorsCompletedAnxiety Disorders | Anxiety | Anxiety Symptoms | Child Anxiety | Anxiety, Mild to Moderate | Pediatric Anxiety DisordersUnited States
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Abant Izzet Baysal UniversityRecruitingAnxiety | Parental AnxietyTurkey (Türkiye)
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Florida State UniversityRecruitingAnxiety | Generalized Anxiety Disorder (GAD) | WorryingUnited States
-
Institut National de la Santé Et de la Recherche...Active, not recruitingAnxiety Disorders | Anxiety | Anxiety and FearFrance
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiActive, not recruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States